Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
FIVE PRIME THERAPEUTICS, INC. (FPRX)
|
Add to portfolio |
|
|
|
| Price: |
$37.94
| | Metrics |
| OS: |
46.6
|
M
| |
-31
|
% ROE
|
| Market cap: |
$1.77
|
B
| |
-40
|
% ROIC
|
|
Net cash:
|
$505
|
M
| |
$10.85
|
per share
|
|
EV:
|
$1.26
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($98.8)
|
M
| |
|
|
|
EBIT
|
($103)
|
M
| |
|
|
| EPS |
($2.69)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| Revenues | 13.2 | 14.9 | 49.9 | 39.5 | 30.7 | 379.8 | 19.2 | 13.8 |
| Revenue growth | -11.4% | -70.2% | 26.2% | 28.7% | -91.9% | 1874.9% | 39.4% | 38.1% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 13.2 | 14.9 | 49.9 | 39.5 | 30.7 | 379.8 | 19.2 | 13.8 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 65.5 | 114.1 | 156.4 | 150.9 | 94.1 | 70.2 | 43.2 | 32.8 |
| General and administrative | 40.6 | 42.7 | 39.7 | 40.0 | 35.8 | 22.6 | 13.6 | 10.4 |
| EBIT | -92.9 | -141.9 | -146.2 | -151.4 | -99.2 | 287.0 | -37.6 | -29.4 |
| EBIT margin | -704.7% | -954.3% | -293.1% | -383.2% | -323.3% | 75.6% | -195.4% | -213.3% |
| Pre-tax income | -91.0 | -137.2 | -140.4 | -148.5 | -96.7 | 287.5 | -37.4 | -28.9 |
| Income taxes | -6.6 | 0.0 | 0.0 | 1.7 | -31.0 | 37.8 | 0.0 | 0.0 |
| Tax rate | 7.3% | 0.0% | 0.0% | | 32.1% | 13.2% | 0.0% | 0.0% |
| Net income | -84.3 | -137.2 | -140.4 | -150.2 | -65.7 | 249.6 | -37.4 | -28.9 |
| Net margin | -639.9% | -922.4% | -281.6% | -380.2% | -214.1% | 65.7% | -194.6% | -209.4% |
| |
| Diluted EPS | ($2.29) | ($3.92) | ($4.13) | ($5.38) | ($2.44) | $9.23 | ($1.79) | ($5.23) |
| Shares outstanding (diluted) | 36.8 | 35.0 | 34.0 | 27.9 | 27.0 | 27.0 | 20.9 | 5.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|